Found: 5
Select item for more details and to access through your institution.
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
- By:
- Publication type:
- Article
Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e164, doi. 10.1016/j.clml.2019.09.275
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e15, doi. 10.1016/j.clml.2019.09.022
- By:
- Publication type:
- Article
Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S326, doi. 10.1016/j.clml.2017.07.136
- By:
- Publication type:
- Article
Sensitive multiple myeloma disease monitoring by mass spectrometry.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 4, p. 1, doi. 10.1038/s41408-021-00473-9
- By:
- Publication type:
- Article